Jump Financial’s Elicio Therapeutics ELTX Stock Holding History

Jump Financial’s Portfolio ELTX Stock Details ELTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-3,150	Closed	-$91K	–	1639
2021 Q4	$91K	Buy	+3,150	New	+$159K	0.01%	1234

Other funds holding ELTX

NCM

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

CM Management Gulf Breeze, Florida $120M AUM 37.12% 1-Year Est. Return

LSAG

Lake Street Advisors Group Portsmouth, New Hampshire $2.17B AUM 16.99% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Jump Financial's ELTX Position: Q1 2022 in Review

Jump Financial sold out of Elicio Therapeutics (ELTX) in Q1 2022, closing a stake of 3,150 shares — an estimated $91K sold.

Jump Financial first reported a position in ELTX in Q4 2021 and held it in 1 quarter. The position peaked at $91K in Q4 2021. 47 funds tracked by Wall St. Rank hold ELTX as of Q1 2022.

Jump Financial reported no remaining Elicio Therapeutics position as of Q1 2022 after selling out during the quarter.
Jump Financial sold 3,150 Elicio Therapeutics shares in Q1 2022, an estimated $91K.
Jump Financial first reported a position in Elicio Therapeutics in Q4 2021 and held it in 1 quarter.
Jump Financial's Elicio Therapeutics position peaked at $91K in Q4 2021.
47 funds tracked by Wall St. Rank held Elicio Therapeutics as of Q1 2022.

Based on Jump Financial's 13F filing for Q1 2022, filed 12 May 2022.